➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Dow
AstraZeneca
Express Scripts

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

ELYXYB Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Elyxyb, and what generic alternatives are available?

Elyxyb is a drug marketed by Dr Reddys and is included in one NDA. There are four patents protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

US ANDA Litigation and Generic Entry Outlook for Elyxyb

A generic version of ELYXYB was approved as celecoxib by MYLAN on May 30th, 2014.

  Start Trial

Summary for ELYXYB
International Patents:16
US Patents:4
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:ELYXYB at DailyMed
Drug patent expirations by year for ELYXYB

US Patents and Regulatory Information for ELYXYB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Dr Reddys ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Dr Reddys ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Dr Reddys ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Dr Reddys ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ELYXYB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731795 10075033 Germany   Start Trial PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Boehringer Ingelheim
Medtronic
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.